Onco-Innovations Advances Nanoparticle PNKP Inhibitor for DNA Damage Response Cancer Therapies
Onco-Innovations advances ONC010™, a nanoparticle PNKP inhibitor, targeting the $7B DDR oncology market. Preclinical success in colorectal cancer models and strategic
2026/06/24